PerkinElmer

PerkinElmer is a global leader committed to innovating for a healthier world. Our dedicated team of employees worldwide are passionate about providing customers with an unmatched experience as they help solve critical issues, especially impacting the diagnostics, discovery and analytical solutions markets.

For our life science research solutions, from basic research and drug discovery to the development and manufacturing of new, significant drugs and clinical treatments, we are helping researchers accelerate the discovery-to-commercialization process, bringing better medicines to market faster. With a comprehensive portfolio from detection and imaging solutions to informatics and services, our forward-minded ideation to advance research possibilities have enabled many methods that once took weeks to perform to now be accomplished in a matter of hours.

Brochure: Biologics workflow solutions brochure

Brochure: Viral research solutions

Brochure: Neuroscience solutions

Brochure: Immuno-Oncology Solutions

Brochure: Diabetes Solutions

Whitepaper: Remdesivir: The technologies behind the discovery

Whitepaper: Virus vaccine research – accelerated workflows

Whitepaper: The impact of COVID-19 on neurological systems

Article: Pharma’s response to COVID-19: What’s next?

ebook: High-content analysis and infectious disease

Application Note: Evaluating the specificity and potency of PD-1 and PD-L1 blocking antibodies using AlphaLISA human and mouse PD-1/PD-L1 binding kits

Application Note: ATPlite assay performance in human primary cells

Tech note: Detection of immune checkpoint markers in peripheral blood mononuclear cell lysates with AlphaLISA

Tech note: Fast, simple, homogeneous assays for characterisation of Fc receptor binding using AlphaLISA

Technical note: 3D volumetric analysis of luminal spaces inside cysts or organoids

Tech note: Long term live cell imaging in a high-content system

Application note: Simultaneous dual phosphoprotein target analysis with Alpha Terbium SureFire Ultra Multiplex

Case Study: Characterisation of hiPSCs by Phenotypic Screening

Application Note: Alpha Terbium SureFire Ultra Multiplex: simultaneous dual phosphoprotein target analysis

Whitepaper: Phenotypic drug discovery with high content screening

Application note: Distinguishing cell types by phenotypic profiling

Tech note: Benefits of water immersion lenses for HCS

Application note: Functional GPCR studies using AlphaScreen cAMP Detection Kit

Application note: LANCE Ultra TR-FRET – based detection and modulation of Phosphorylated STAT3 levels in human cells

Application note: Fc-Receptor binding in ADCC assays utilising LANCE Ultra Technology – characterisation of hIGs and FcγRIIIa

Application note: High throughput quantitation of cytokine biomarkers using LANCE Ultra TR-FRET assays

Application note: Development and utilisation of bromodomain and extra terminal domain (BET) assays using AlphaLISA technology

Scientific poster: Developing protein: Protein Interaction (PPI) assays with AlphaLISA and LANCE TR-FRET

Application note: Screening for inhibitors of PD-1 and PD-L1 binding with AlphaLISA technology

Application note: Characterising chemokine receptor inhibitors with Alpha SureFire Ultra assays

Webinar highlights: Harmonising drug-target binding data analytics on a single platform

Webinar preview: Compliance with data integrity and computerised system validations

Assays In-Depth Focus 2018

Expert view: Assays to measure the potency of therapeutic antibodies used in combination with other drugs for Immuno‑Oncology treatments

Streamlining drug discovery assays for cancer and cardiovascular disease

Screening In-Depth Focus 2018

Expert view: Toward physiological relevance in drug discovery and development

Streamlining drug discovery assays for cancer and cardiovascular disease

Expert view: Improving hit-to-lead results

Screening In-Depth Focus 2017

Expert view: Innovations in 3D

NGS In-Depth Focus 2017

Assays In-Depth Focus 2017

Drug Target Review – Issue #3 2017

Screening In-Depth Focus 2017

High-throughput calcium flux assays: luminescent versus fluorescent readout

Workshop Review: Cell-based Assays for Screening (December 2014)

Cell-based assays market set to exhibit CAGR of 8.5 percent

Label-free array system market to be worth $1,600 million by 2025, study finds

PerkinElmer launches new IVIS® Lumina™ S5 and Lumina X5 systems for high throughput in vivo imaging

PerkinElmer launches next generation high content screening system

Video: PerkinElmer signals lead discovery

Cellular Thermal Shift Assays – bringing relevant target engagement to your drug discovery workflow

Next generation strategies for cancer immunotherapy

Establishing Alpha CETSA HT in primary screening

Harmonising drug-target binding data analytics on a single platform

Compliance with data integrity and computerised system validations

Streamlining drug discovery assays for cancer and cardiovascular disease

High performance computing for high content screening – A case study